Fava M,Kendler KS .2000 .Major depressive disorder. Neuron, 28 : 335-41.
National .2010 .Institute for Health and Clinical Excellence. [Last accessed on 2013, Aug, 6 : .
.2013 .. Diagnostic and Statistical Manual of Mental Disorders. DSM‑5, : .
Waraich P,Goldner EM,Somers JM,Hsu L JM .2004 .Prevalence and incidence studies of mood disorders: A systematic review of the literature. Can J Psychiatry, 49 : 1243-8.
Kessler RC,Berglund P,Demler O,Jin R,Koretz D,Merikangas KR .2003 .The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS‑R). JAMA, 289 : 3095-105.
Davis KL,Charney D,Coyle JT,Nemeroff C,Williams C .2002 .We i s m a n n M M . R i s k f a c t o r s f o r m a j o r d e p re s s i o n a n d b i p o l a r d i s o rd e r. Neuropsychopharmacology: The Fifth Generation of Progress. , : .
Fawcett J. .1993 .The morbidity and mortality of clinical depression. Int Clin Psychopharmacol, 8 : 217-20.
Holma KM,Melartin TK,Haukka J,Holma IA,Sokero TP,Isometsa ET .2010 .Incidence and predictors of suicide attempts in DSM‑IV major depressive disorder: A five‑year prospective study. Am J Psychiatr, 167 : 801-8.
Osby U,Brandt L,Correia N,Ekbom A,Sparen P .2001 .Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry, 58 : 844-50.
Administration Drug . .B u d e p r i o n X L 3 0 0 m g n o t t h e r a p e u t i c a l l y equivalent to Wellbutrin 300 mg. [Last accessed on 2013, Aug, 6 : .
Woodcock J,Khan M,Yu L X. M .2012 .Withdrawal of generic budeprion for nonbioequivalence. N Engl J Med, 367 : 2463-5.
. .Practice guideline for the treatment of patients with major depressive disorder. id=24158. [Last accessed on 2013, Aug, 6 : .
Wimbiscus M,Kostenko O,Malone D. .2010 .MAO inhibitors: Risks, benefits, and lore. Cleve Clin J Med, 77 : 8598-2.
WELLBUTRIN XL .2008 .Prescribing information. , : .
Stahl SM .2009 .Mechanism of action of trazodone: A multifunctional drug. CNS Spectr, 14 : 536-46.
Stahl SM .2009 .Multifunctional drugs: A novel concept for psychopharmacology. CNS Spectr, 14 : 71-3.
.2007 .Soltab US prescribing information. , : .
REMERON ,Organon N.V. .2011 .® (mirtazapine) prescribing information. Oss, : .
Schatzberg AF .2007 .Safety and tolerability of antidepressants: Weighing the impact on treatment decisions. J Clin Psychiatry, 68(Suppl 8) : 26-34.
Qaseem A,Snow V,Denberg TD,Forciea MA,Owens DK .2008 .Using second‑generation antidepressants to treat depressive disorders: A clinical practice guideline from the American College of Physicians. Ann Intern Med, 149 : 725-33.
Keller MB,Hirschfeld RM,Demyttenaere K,Baldwin DS .2002 .Optimizing outcomes in depression: Focus on antidepressant compliance. Int Clin Psychopharmacol, 17 : 265-71.
Anderson IM,Ferrier IN,Baldwin RC,Cowen PJ,Howard L,Lewis G .2008 .Evidence‑based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol, 22 : 343-96.
Bauer M,Monz BU,Montejo AL,Quail D,Dantchev N,Demyttenaere K .2008 .Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry, 23 : 66-73.
Hansen RA,Gartlehner G,Lohr KN,Gaynes BN,Carey TS .2005 .Efficacy and safety of secondg‑eneration antidepressants in the treatment of major depressive disorder. Ann Intern Med, 143 : 415-26.
Williams JW,Mulrow CD,Chiquette E,Noel PH,Aguilar C,Cornell J. .2000 .A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med, 132 : 743-56.
Gartlehner G,Hansen RA,Morgan LC,Thaler K,Lux L,Van Noord M .2011 .Comparative benefits and harms of second‑generation antidepressants for treating major depressive disorder: An updated meta‑analysis. Ann Intern Med, 155 : 772-85.
Gartlehner G,Gaynes BN,Hansen RA,Thieda P,DeVeaugh‑Geiss A,Krebs EE .2008 .Comparative benefits and harms of second‑generation antidepressants: Background paper for the American College of Physicians. Ann Intern Med, 149 : 734-50.
Mackay FR,Dunn NR,Martin RM,Pearce GL,Freemantle SN,Mann RD .1999 .Newer antidepressants: A comparison of tolerability in general practice. Br J Gen Pract, 49 : 892-6.
DeVane CL .2003 .Immediater‑elease versus controlledr‑elease formulations: Pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry, 64(Suppl 18) : 14-9.
Golden RN,Nemeroff CB,McSorley P,Pitts CD,Dube EM .2002 .Efficacy and tolerability of controlled‑release and immediate‑release paroxetine in the treatment of depression. J Clin Psychiatry, 63 : 577-84.
Nemeroff CB .2003 .Improving antidepressant adherence. J Clin Psychiatry, 64(Suppl 18) : 25-30.
Siegel SJ .2005 .Extended release drug delivery strategies in psychiatry: Theory to practice. Psychiatry (Edgmont), 2 : 22-31.
Singh MN,Hemant KS,Ram M,Shivakumar HG .2010 .Microencapsulation: A promising technique for controlled drug delivery. Res Pharm Sci, 5 : 65-77.
Nitti VW,Sanders S,Staskin DR,Dmochowski RR,Sand PK,MacDiarmid S .2006 .Transdermal delivery of drugs for urologic applications: Basic principles and applications. Urology, 67 : 657-64.
Kurz A,Farlow M,Lefevre G .2009 .Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review. Int J Clin Pract, 63 : 799-805.
.2011 .. , : .
Claxton A,de Klerk E,Parry M,Robinson JM,Schmidt ME JM .2000 .Patient compliance to a new enteric‑coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry, 61 : 928-32.
.2001 .Patient compliance with enteric‑coated weekly fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatr y, 62(Suppl 22) : 43-7.
Schmidt ME,Fava M,Robinson JM,Judge R. .2000 .The efficacy and safety of a new enteric‑coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry, 61 : 851-7.
Dinan TG .2001 .Efficacy and safety of weekly treatment with entericc‑oated fluoxetine in patients with major depressive disorder. J Clin Psychiatry, 62(Suppl 22) : 48-52.
Burke WJ,Hendricks SE,McArthur‑Miller D,Jacques D,Bessette D,McKillup T .2000 .Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: Results of a placeboc‑ontrolled, randomized clinical trial. J Clin Psychopharmacol, 20 : 423-7.
Wagstaff AJ,Goa KL .2001 .Once‑weekly fluoxetine. Drugs, 61 : 2221-8.
EFFEXOR XR .2011 .® prescribing information. , : .
Cunningham L A .1997 .Once‑daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry, 9 : 157-64.
Entsuah R,Chitra R. .1997 .A benefit‑risk analysis of once‑daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull, 33 : 671-6.
Haeusler JM .2009 .Change in formulation and its potential clinical and pharmacoeconomic value: Example of extended release venlafaxine. Curr Med Res Opin, 25 : 1089-94.
Mann JJ,Aarons SF,Wilner PJ,Keilp JG,Sweeney JA,Pearlstein T .1989 .A controlled study of the antidepressant efficacy and side effects of (‑)‑deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry, 46 : 45-50.
Sunderland T,Cohen RM,Molchan S,Lawlor BA,Mellow AM,Newhouse PA .1994 .High‑dose selegiline in treatment‑resistant older depressive patients. Arch Gen Psychiatry, 51 : 607-15.
Patkar AA,Pae CU,Masand PS .2006 .The new generation of monoamine oxidase inhibitors. CNS Spectr, 11 : 363-75.
Bodkin JA,Amsterdam JD .2002 .Transdermal selegiline in major depression: A double‑blind, placebo‑controlled, parallel‑group study in outpatients. Am J Psychiatry, 159 : 1869-75.
United ,SomersetE‑MSAM .2005 .States Food and Drug Administration. EMSAM, Selegiline Transdermal System. [Last accessed on 2013, Aug, 6(336) : 01.
Halaris AE,Stern WC,Van Wyck Fleet J,Reno RM .1983 .Evaluation of the safety and efficacy of bupropion in depression. J Clin Psychiatry, 44 : 101-3.
Lineberry CG,Johnston JA,Raymond RN,Samara B,Feighner JP,Harto NE .1990 .A fixed‑dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry, 51 : 194-9.
Zung WW,Brodie HK,Fabre L,McLendon D,Garver D .1983 .Comparative efficacy and safety of bupropion and placebo in the treatment of depression. Psychopharmacology (Berl), 79 : 343-7.
Fabre LF,Brodie HK,Garver D,Zung WW D .1983 .A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J Clin Psychiatry, 44 : 88-94.
Reimherr FW,Cunningham LA,Batey SR,Johnston JA,Ascher JA. .1998 .A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustainedr‑elease bupropion tablets versus placebo in depressed outpatients. Clin Ther, 20 : 505-16.
Jefferson JW,Rush AJ,Nelson JC,VanMeter SA,Krishen A,Hampton KD .2006 .Extended‑release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: Findings from a randomized, doubleb‑lind, placeboc‑ontrolled study. J Clin Psychiatry, 67 : 865-73.
Fava M,Rush AJ,Thase ME,Clayton A,Stahl SM,Pradko JF .2005 .15 years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry, 7 : 106-13.
Jefferson JW,Pradko JF,Muir KT .2005 .Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther, 27 : 1685-95.
Administration Drug . .Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. [Last accessed on 2013, Aug, 6 : .
.2008 .Wellbutrin versus generic bupropion. Med Lett Drugs Ther, 50 : 54-5.
Administration Drug .2009 .Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg. , : .
. .Generic bupropion is not always identical to Wellbutrin. Are you getting what you expect? 2007. [Last accessed on 2013, Aug, 6 : .
Chenu F,Batten LA,Zernig G,Ladstaetter E,Hebert C .2009 .Comparison of pharmacokinetic profiles of brand‑name and generic formulations of citalopram and venlafaxine: A crossover study. J Clin Psychiatry, 70 : 958-66.
Correll CU,Carbon M. .2012 .A v a i l a b l e f r o m : h. , : 38.
Desmarais JE,Beauclair L,Margolese HC .2011 .Switching from brand‑name to generic psychotropic medications: A literature review. CNS Neurosci Ther, 17 : 750-60.
Vlahiotis A,Devine ST,Eichholz J,Kautzner A .2011 .Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. J Manag Care Pharm, 17 : 123-32.
.2011 .US prescribing information. , : .
CYMBALTA .2011 .® prescribing information. , : .
NC .2011 .US prescribing information. , : .
PAXIL CR,NC CR .2011 .US prescribing information. , : .
EMSAM .2008 .® (SELEGILINE TRANSDERMAL SYSTEM) prescribing information. , : .
Sajatovic M,Handiwala L. .2013 .Clinical perspectives on the inuflence of drug formulation on patient tolerability and use of commonly prescribed antidepressants in major depressive disorder. Arch Pharma Pract, 4 : 83-92.